Target intelligence / Profile preview

Multidrug and toxin extrusion transporter 1 (MATE1)

Target
MATE1
Molecular classification
Transporter, Proton antiporter, Solute carrier family
01

Overview

Multidrug and toxin extrusion transporter 1 (MATE1) is an apically expressed, polyspecific proton/drug antiporter protein primarily found in the brush-border membrane of renal proximal tubule and canalicular membrane of hepatocytes, where it functions to export endogenous and exogenous cations and some anions into urine and bile using an outward proton gradient as the driving force. Encoded by the SLC47A1 gene, MATE1 plays a central role in the renal and hepatic elimination of many drugs, toxins, and metabolites—including metformin, cimetidine, and cisplatin—and is implicated in clinically meaningful drug-drug interactions and inter-individual differences in drug responses. MATE1 is considered a clinically significant transporter for regulatory pharmacokinetic studies and risk assessment[1][4][5][6][7].

Other names
Multidrug and toxin extrusion protein 1Solute carrier family 47 member 1SLC47A1
02

Mechanism of action

Substrate efflux via proton antiport (transports cationic and some anionic drugs/toxins from cells into urine or bile in exchange for protons) Inhibitors block or reduce efflux, altering drug concentrations and contributing to drug-drug interactions

03

Biological functions

Renal drug excretionBiliary drug excretionDetoxificationHomeostasis of electrolytes and metabolites
04

Disease associations

Cancer (relevance in pharmacokinetics of chemotherapeutics, e.g., cisplatin)Drug-induced toxicity (notably nephrotoxicity)Pharmacogenetic effects impacting drug efficacy/safetySmith–Magenis syndrome (gene location within syndrome-critical region)
05

Safety considerations

Drug-drug interactions due to competitive inhibition or reduced function (risk with metformin, cisplatin, cimetidine, and others)Altered drug elimination/toxicity risk in patients with genetic variants affecting transporter functionPotential impact on nephrotoxicity of chemotherapeutics
06

Interacting drugs

Metformin

15 more in the full profile.

07

Biomarkers

SLC47A1 gene polymorphisms (affect metformin pharmacokinetics/efficacy)MATE1 expression levels (may inform susceptibility to drug toxicity or dosing strategies)

Beyond the preview

Go deeper on Multidrug and toxin extrusion transporter 1 (MATE1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multidrug and toxin extrusion transporter 1 (MATE1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call